458 related articles for article (PubMed ID: 15847207)
1. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
Magen E; Elbirt D; Sthoeger Z
Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
[TBL] [Abstract][Full Text] [Related]
2. Dyslipidaemia and cardiovascular risk in HIV infection.
Kulasekaram R; Peters BS; Wierzbicki AS
Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular disease and toxicities related to HIV infection and its therapies.
Zareba KM; Miller TL; Lipshultz SE
Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus and atherosclerosis.
Farrugia PM; Lucariello R; Coppola JT
Cardiol Rev; 2009; 17(5):211-5. PubMed ID: 19690471
[TBL] [Abstract][Full Text] [Related]
5. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
6. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
Calza L; Manfredi R; Pocaterra D; Chiodo F
J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
Grinspoon S; Carr A
N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
[No Abstract] [Full Text] [Related]
8. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
[TBL] [Abstract][Full Text] [Related]
9. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L; Manfredi R; Chiodo F
J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
[TBL] [Abstract][Full Text] [Related]
11. Risk of cardiovascular disease in HIV-infected patients.
Das S
J Antimicrob Chemother; 2010 Mar; 65(3):386-9. PubMed ID: 20026610
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy with heart.
Randell P; Moyle G
Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
[TBL] [Abstract][Full Text] [Related]
13. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
Crook M
Ann Clin Biochem; 2007 May; 44(Pt 3):219-31. PubMed ID: 17456292
[TBL] [Abstract][Full Text] [Related]
14. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
Grover SA; Coupal L; Gilmore N; Mukherjee J
Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
[TBL] [Abstract][Full Text] [Related]
15. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
Leclercq P; Blanc M
Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
[TBL] [Abstract][Full Text] [Related]
16. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006).
Carosi G; Quiros-Roldan E; Torti C; Antinori A; Bevilacqua M; Bonadonna RC; Bonfanti P; Castagna A; Cauda R; d'Arminio-Monforte A; Di Gregorio P; Di Perri G; Esposito R; Fatuzzo F; Gervasoni C; Giannattasio C; Guaraldi G; Lazzarin A; Lo Caputo S; Maggi P; Mazzotta F; Moroni M; Prestileo T; Ranieri R; Rizzardini G; Russo R; Galli M;
Infection; 2007 Jun; 35(3):134-42. PubMed ID: 17565453
[TBL] [Abstract][Full Text] [Related]
17. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
18. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
19. Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy.
Venkat A; Piontkowsky DM; Cooney RR; Srivastava AK; Suares GA; Heidelberger CP
Ann Emerg Med; 2008 Sep; 52(3):274-85. PubMed ID: 18358567
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness.
Vergara-Rodriguez P; Vibhakar S; Watts J
Pharmacol Ther; 2009 Dec; 124(3):269-78. PubMed ID: 19647020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
